Themis Medicare Reports Rs 28.74 Cr Profit in Q1 FY27 Driven by Rs 99.67 Cr Investment Sale

Themis Medicare Ltd. announced its unaudited standalone financial results for the quarter ended June 30, 2026, reporting a net profit of Rs. 28.74 crore. This marks a significant turnaround from a net loss of Rs. 15.37 crore in the same quarter of the previous year.

Reader Takeaway: Exceptional gain boosts profit; core revenue declines.

What just happened

The company's standalone net profit after tax (PAT) for the June 2026 quarter stood at Rs. 28.74 crore. This profit includes an exceptional gain of Rs. 99.67 crore derived from the sale of its investment in Gujarat Themis Biosyn Limited. The revenue from operations for the quarter was Rs. 86.96 crore, a decrease from Rs. 97.58 crore in the corresponding quarter of the previous year.

Why this matters

The substantial profit reported for the quarter is primarily due to a one-time event – the sale of an investment. While this boosts the bottom line significantly, the decline in operational revenue suggests a need for closer scrutiny of the company's core business performance in the coming periods. The appointment of a new Company Secretary also signifies an update in corporate governance.

The backstory

In the quarter ended June 30, 2025, Themis Medicare reported a standalone net loss of Rs. 15.37 crore on revenues of Rs. 97.58 crore. The current quarter's results reflect a shift to profitability, largely influenced by strategic asset divestment. The company sold 2,497,190 equity shares of its associate, Gujarat Themis Biosyn Limited, for Rs. 100 crore, realizing an exceptional profit of Rs. 99.67 crore.

What changes now

Investors will now look for sustained profitability from core operations rather than relying on one-off gains. The company has also appointed Mr. Suresh Savaliya as its new Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP), effective August 13, 2026. Mr. Savaliya brings 23 years of experience and has previously worked with large conglomerates.

Risks to watch

The primary risk for investors is the reliance on exceptional items for profit generation. A decline in core revenue without a corresponding increase in profitability from ongoing operations could be a concern. Investors should monitor the company's ability to grow its revenue and maintain profitability from its pharmaceutical and healthcare businesses.

Peer comparison

(No specific peer data available in the filing. A general comparison would involve looking at other mid-cap pharmaceutical companies focusing on revenue growth, Ebitda margins, and return ratios, while accounting for their own unique business models and product pipelines.)

Context metrics (time-bound)

• Standalone Revenue from Operations: Rs. 86.96 crore (Q1 FY27) vs Rs. 97.58 crore (Q1 FY26) - down 10.9%
• Standalone Profit After Tax: Rs. 28.74 crore (Q1 FY27) vs (Rs. 15.37 crore) (Q1 FY26) - turnaround to profit
• Exceptional Gain: Rs. 99.67 crore from sale of investment in Gujarat Themis Biosyn Limited.
• EPS (Basic): Rs. 3.12 (Q1 FY27) vs (Rs. 1.67) (Q1 FY26).

What to track next

Investors should track the company's performance in the upcoming quarters to assess the sustainability of its profitability and any potential recovery in operational revenue. The integration and impact of the new Company Secretary on governance practices will also be something to observe.